>From the Division of Pulmonology, University Hospital Zurich, 8091 Zurich, Switzerland; and the Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland.
Exp Clin Transplant. 2024 Sep;22(9):698-705. doi: 10.6002/ect.2024.0186.
Recent advancements in lung transplantation have expanded donor and candidate criteria, challenging multidisciplinary teams to navigate ethical and clinical complexities in patient selection and management. Comorbidities and frailty substantially influence outcomes posttransplant, yet optimal assessment tools for frailty remain undetermined. This study investigated whether preoperative comorbidity and frailty assessments predict postoperative outcomes in lung transplant recipients.
In this retrospective cohort study, we analyzed 68 adult patients who underwent single or bilateral lung transplant at the University Hospital Zurich in Zurich, Switzerland, between January 2022 and December 2023. We assessed comorbidity and frailty data by using the Varughese 40-variable frailty index and categorized deficits in comorbidity, laboratory values, and functional status. We classified comorbidity on the basis of prevalent diseases.
Among the cohort, 62 patients underwent bilateral transplant, including 2 patients who required retransplant. Of total patients, 42 were male patients, and mean age at transplant was 58 years. Mortality rates were notably higher among patients with 6 or more comorbidities compared patients who had less comorbidities, although definitive conclusions were limited by the small sample size (n = 5). Frailty index scores ranged from 0.05 to ≥0.20, with no scores below 0.05 observed. Higher frailty index (≥0.20) correlated with prolonged intensive care unit,thoracic ward, and rehabilitation center stays, as well as increased total hospitalization days and mortality, albeit with a small sample size limitation.
This study assessed the effects of preoperative comorbidity and frailty on postoperative outcomes in lung transplant recipients. Higher comorbidity counts were linked to increased mortality, with 38% of patients with 6 or more comorbidities dying within the first year. A higher frailty index (≥0.20) was associated with longerintensive care unit, normal ward, and rehabilitation stays, higher total hospitalization days, and increased mortality.
肺移植领域的最新进展扩大了供体和候选者标准,这使得多学科团队在患者选择和管理方面面临着伦理和临床复杂性的挑战。合并症和虚弱显著影响移植后的结果,但目前仍缺乏评估虚弱的最佳工具。本研究旨在探讨肺移植受者术前合并症和虚弱评估是否可预测术后结局。
在这项回顾性队列研究中,我们分析了 2022 年 1 月至 2023 年 12 月期间在瑞士苏黎世大学医院接受单肺或双肺移植的 68 名成年患者。我们使用 Varughese 40 变量虚弱指数评估合并症和虚弱数据,并对合并症、实验室值和功能状态的缺陷进行分类。我们根据现有疾病对合并症进行分类。
该队列中,62 名患者接受了双肺移植,其中 2 名患者需要再次移植。在所有患者中,42 名是男性患者,移植时的平均年龄为 58 岁。患有 6 种及以上合并症的患者死亡率明显高于合并症较少的患者,但由于样本量小(n=5),无法得出明确结论。虚弱指数评分范围为 0.05 至≥0.20,未观察到评分低于 0.05。较高的虚弱指数(≥0.20)与重症监护病房、胸科病房和康复中心停留时间延长以及总住院天数和死亡率增加相关,尽管存在样本量小的限制。
本研究评估了肺移植受者术前合并症和虚弱对术后结局的影响。较高的合并症计数与死亡率增加相关,6 种及以上合并症患者中有 38%在术后 1 年内死亡。较高的虚弱指数(≥0.20)与重症监护病房、普通病房和康复病房停留时间延长、总住院天数增加和死亡率增加相关。